Conditional sentence,
Brain,
Drug,
Enzyme,
Patient,
Bone marrow,
Acetone,
Organelle,
Soybean,
Inflammation,
Methane,
Protein,
Cell,
Laboratory,
Mineral,
Pregnancy,
Blood,
Yolk,
Health,
Apoptosis,
Human body,
Death,
Research,
Vitamin,
Water,
Carbon,
Functional food,
Phospholipid,
Kaifeng,
Dietary fiber,
Disease,
Convalescence,
Agonal respiration,
Human,
Mitochondrion,
SISI,
Food,
Medicine,
PC,
Golgi,
Carbohydrate,
Nutrient,
Beauty,
Signal transduction,
Temperature,
Ageing,
Microsome,
Lipid,
Cell damage,
Malabsorption,
Growth,
Fats,
Phosphorus Cells are the basic units of life, and the health and vitality of cells directly affect the health of the entire body.
Key Points:
- Cells are the basic units of life, and the health and vitality of cells directly affect the health of the entire body.
- Cells need to continuously obtain nutrients from the external environment to support their normal growth, division and metabolic activities.
- When cells receive sufficient and balanced nutrients, they can maintain optimal conditions, perform various life activities, and maintain cell health.
- The layout of the three major fields will create natural active water phospholipids into a super new category in the health industry.
BEIJING, March 12, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that on March 11, 2024, the Company received formal notice from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company has evidenced compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule5550(a)(2).
Key Points:
- BEIJING, March 12, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that on March 11, 2024, the Company received formal notice from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company has evidenced compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule5550(a)(2).
- The notice indicated that as a result of the closing bid price of the Company’s common stock having been at least $1.00 per share for the period of 15 consecutive business days, from February 16,, 2024, to March 8, 2024, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and advised that this matter is now closed.
Retrieved on:
Wednesday, February 14, 2024
The Company is effecting the reverse split to regain compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).
Key Points:
- The Company is effecting the reverse split to regain compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).
- The rights and privileges of the holders of shares of Common Stock will be substantially unaffected by the reverse stock split.
- Transhare Corporation is acting as transfer and exchange agent for the reverse stock split.
- Registered shareholders who hold shares of Common Stock are not required to take any action to receive post-reverse stock split shares.
Retrieved on:
Friday, November 17, 2023
Zhuhai City Polytechnic,
China National Silk Museum,
Investment,
City,
Woman,
Alberta Enterprise Group,
New star,
Gold,
Commerce,
Strategic planning,
Advanced Individual Combat Weapon,
Partner,
Southwest University,
Marketing,
SISI,
Partnership,
Business administration,
Clothing,
University,
Research fellow,
Chairperson,
University of Northern Virginia,
Master,
Female,
Management,
Hong Kong Effective November 13, 2023, Shineco’s Board of Directors appointed Ms. Xiaohui Wang as Executive President of the Company.
Key Points:
- Effective November 13, 2023, Shineco’s Board of Directors appointed Ms. Xiaohui Wang as Executive President of the Company.
- From February 1991 to March 2000, Ms. Wang worked as Manager at Chongqing Silk Import and Export Company where she was responsible for the company's import and export management.
- Effective November 13, 2023, Shineco’s Board of Directors appointed Mr. Chi Keung Yan as the Chief Strategy Officer of the Company.
- Ms. Jennifer, CEO of Shineco, said, "We are pleased to welcome Ms. Wang and Mr. Yan to our leadership team.
Taste,
Dartmouth College,
Health,
Food,
SISI,
Lipid metabolism,
Research,
Metabolism,
Trust,
Peking Union Medical College,
Hormone,
Safety,
Insulin resistance,
Hygiene,
Glucose,
Insulin,
Dietary supplement BEIJING, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today the grand opening of its first carry-out restaurant which will sell Shineco’s new healthy and nutritious food brand, ‘Meida Nutritionary Restaurant”. Shineco’s first carry-out restaurant is located on Baihuazhou Road, Cangshan, Fuzhou City, China. Shineco’s official entry into the healthy food market represents a further evolution of the medical and health company’s operations, which has been long engaged in the field of life sciences.
Key Points:
- BEIJING, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today the grand opening of its first carry-out restaurant which will sell Shineco’s new healthy and nutritious food brand, ‘Meida Nutritionary Restaurant”.
- Dr. Fengming Liu, the leader of Shineco’s Healthy Food Project, has a doctorate from Peking Union Medical College and is a postdoctoral fellow at Dartmouth College.
- Shineco decided to enter the healthy food market in order to introduce life science concepts that encompass nutrition, health, and functionality while maintaining convenience, speed and taste.
- The healthy carry-out meals launched by Shineco incorporates life science research that has given rise to using food to regulate insulin resistance and improve glucose and lipid metabolism.
Retrieved on:
Wednesday, October 4, 2023
BEIJING, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer of innovative diagnostic medical products and related medical devices announced today that it plans to increase its research and development of new high-tech applications of silk protein in the health and medical field in conjunction with its existing silkworm business segment.
Key Points:
- BEIJING, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer of innovative diagnostic medical products and related medical devices announced today that it plans to increase its research and development of new high-tech applications of silk protein in the health and medical field in conjunction with its existing silkworm business segment.
- Dream Partner owns 100% of Chongqing Wintus Group (“Chongqing Wintus”), a manufacturer of antibacterial and antiviral fabrics using mulberry silk as its raw material.
- Chongqing Wintus has production bases, processing plants and mulberry silk technology innovation centers in India, mainland China and Hong Kong.
- Based on its unique technological advantages, the Company will explore the application of silk protein in such areas as medical dressings, medical textiles, among other fields, focusing on developing new products with high added value.
Marketing,
SISI,
ECG,
Splenic infarction,
Prognosis,
Temperature,
Hospital,
Patient,
Collection,
Myoglobin,
AMI,
Distribution,
National Medical Products Administration,
Diagnosis,
Cardiology,
Transport,
FDA,
SATRO-ECG,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Heart,
Food,
NMPA,
Medical device BEIJING, July 10, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer of technologically advanced healthcare products and services, announced today that on June 21, 2023, Changzhou Biowin Pharmaceutical Co., Ltd., a majority-owned subsidiary of the Company ("Biowin"), received marketing and distribution approval for its Cardiac 5-Minute Test from the Jiangsu Bureau of the National Medical Products Administration (“NMPA"), which is China’s regulatory equivalent of the U.S. Food and Drug Administration (FDA). The effective date for the diagnostic medical product’s registration with the NMPA is June 21, 2023, and it shall remain valid for five years through June 20, 2028.
Key Points:
- The Cardiac 5-Minute Test is a combination test of three major cardiac markers and can detect cardiac troponin I, myoglobin, and heart fatty acid binding protein for the clinical diagnosis of acute myocardial infarction (“AMI”) in one test.
- "We are very glad to have received marketing approval for our Cardiac 5-Minute Test from the NMPA.
- We believe that the regulatory approval of our Cardiac 5-Minute Test will ultimately lead to substantial profitability for the Company,” concluded Dr. Liu, CEO of Biowin.
- We believe that the Cardiac 5-Minute Test will have a wide range of point-of-service administration including hospitals, emergency rooms, cardiology departments, and doctor’s offices.
BEIJING, June 28, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that on June 15, 2023, its wholly owned subsidiary, Shineco Life Science Research Co., Ltd. (“Shineco Life Science”), signed a joint venture cooperation agreement (the “Agreement”) with Yangzhou Kangling Medical Co., Ltd. ("Kangling Medical"), to establish a joint venture company, Shangkang Life Science and Technology (Jiangsu) Co., Ltd (“Shangkang Life Science”).
Key Points:
- BEIJING, June 28, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that on June 15, 2023, its wholly owned subsidiary, Shineco Life Science Research Co., Ltd. (“Shineco Life Science”), signed a joint venture cooperation agreement (the “Agreement”) with Yangzhou Kangling Medical Co., Ltd. ("Kangling Medical"), to establish a joint venture company, Shangkang Life Science and Technology (Jiangsu) Co., Ltd (“Shangkang Life Science”).
- The joint venture will be formed to improve the delivery of healthcare services and medical products throughout China.
- Kangling Medical, formerly known as Jiangdu Medical Electronic Equipment Enterprise, was established in 1997 in Jiangsu Province, China, and the ‘Kangling’ brand is recognized in China for its premier medical products.
- The cooperation between our two parties will expand our global sales channels and Shineco’s resources will vastly improve the research and development capabilities of Kangling Medical.”
BEIJING, June 08, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that in May 2023, its wholly owned subsidiary. Shineco Life Science Research Co., Ltd., was registered as a member of the All-China Federation of Industry and Commerce Medical & Pharmaceutical Chamber of Commerce (the “Pharmaceutical Chamber of Commerce”), and Ms. Jennifer Zhan, CEO of Shineco, became a member of the Pharmaceutical Chamber of Commerce.
Key Points:
- Shineco Life Science Research Co., Ltd., was registered as a member of the All-China Federation of Industry and Commerce Medical & Pharmaceutical Chamber of Commerce (the “Pharmaceutical Chamber of Commerce”), and Ms. Jennifer Zhan, CEO of Shineco, became a member of the Pharmaceutical Chamber of Commerce.
- The Pharmaceutical Chamber of Commerce is a national level association that operates directly under the All-China Federation of Industry and Commerce and is registered with China’s Ministry of Civil Affairs.
- The Pharmaceutical Chamber of Commerce consists of a wide array of pharmaceutical enterprises throughout China, and it serves as an important link to the government, supports the interests of its members and serves as a platform for promoting the industry’s development.
- Ms. Jennifer Zhan, CEO of Shineco, commented, “We are pleased that Shineco Life Science Research has been registered with the All-China Federation of Industry and Commerce Medical & Pharmaceutical Industry Chamber of Commerce.
Heart,
Myocardial infarction,
Marketing,
SISI,
Survival,
Cosmetics,
Facial muscles,
Patient,
Risk,
AMI,
National Medical Products Administration,
Diagnosis,
FDA,
NMPA,
Safety,
Medical device BEIJING, April 04, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer and distributor of Chinese herbal medicines, organic agricultural products and other biotech products, announced today that its Cardiac 5-Minute Test, developed by its 51%-owned subsidiary Changzhou Biowin Pharmaceutical Co., Ltd. (“Biowin”), passed quality inspection by the Anhui Bureau of the National Medical Products Administration (“NMPA"), China’s regulatory body that supervises the safety and registration of drugs, medical devices and cosmetics.
Key Points:
- This milestone is vital for the Company since it provides strong support for the product's marketing in China which is expected to occur in the near future.
- Dr. Marvin Liu, CEO of Biowin, commented, “We are pleased to announce that the Cardiac 5-Minute Test has successfully passed quality inspection by China’s NMPA, which is similar to the FDA in the US.
- For patients with a myocardial infarction (AMI), blood flow to the heart is blocked and the heart muscle can be damaged.
- The integration of Biowin in our upgraded value chain is consistent with our goal to maximize shareholder returns.”
